Browsing by Author "nurten eskiyurt"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Günlük veya haftalık alendronat veya risendronat alan postmenopozal osteoporozlu kadınlarda aylık ibandronat için hasta tercihinin değerlendirildiği açık- etiketli, prospektif, çok-merkezi, iki-aşamalı çalışma-BONCURE: Türkiye alt-çalışması
    (2012) Bülent BÜTÜN; Kazım ŞENEL; Hatice Sema Oncel; Vesile SEPİCİ; Savas Gursoy; HÜSEYIN DEMIR; nurten eskiyurt; Ferhan CANTÜRK; F. Yesim Gokce Kutsal; Jale İRDESEL; Yeşim Kirazlı; Hatice UĞURLU; Mehmet Tosun; Peyman YALÇIN; Lale Cerrahoglu; Fisun Ardic Yukruk; Ömer Faruk ŞENDUR; FEVZİYE MERİH SARIDOĞAN; GULSEREN AKYUZ; TUNAY SARPEL; Hakan ÖNCEL; fatih ozdener
    Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered “YES” to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4 points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (≥80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012;18:1-7)
  • No Thumbnail Available
    Item
    Demographic and clinical characteristics of inpatient stroke patients in Turkey
    (2022) tiraje tuncer; Neşe Özgirgin; Saliha Eroğlu demir; Sibel Basaran; Gulcan Ozturk; Özlem ALTINDAĞ; Berrin GÜNDÜZ; Nurdan Paker; hulya ARIKAN; Necmettin Yıldız; Figen Yilmaz; OZLEM SATIR; Derya Bugdayci; Duygu Geler Külcü; banu kuran; ali yavuz karahan; AYSE YALIMAN; Serpil Savaş; canan Tıkız; Ilknur Aktas; Ayşe Nur Bardak; Berna Celik; gülgün durlanık; jülide öncü; Berrin Hüner; belgin erhan; nurten eskiyurt; Fatma Merih Akpınar; Nilgun Simsir Atalay; erkan kaya; Aylin SARI; Gulcin Kaymak Karatas; Ozden Ozyemisci-Taskiran; Beril DOĞU; Demet UÇAR; Feyza Unlu Ozkan
    Objectives: This study aims to assess the stroke rehabilitation facilities provided by university hospitals (UHs) and training and research hospitals (TRHs) and to evaluate the geographical disparities in stroke rehabilitation. Patients and methods: Between April 2013 and April 2014 a total of 1,529 stroke patients (817 males, 712 females; mean age: 61.7±14.0 years; range, 12 to 91 years) who were admitted to the physical medicine and rehabilitation clinics in 20 tertiary care centers were retrospectively analyzed. Demographic, regional and clinical characteristics, details of rehabilitation period, functional status, and complications were collected. Results: The median duration of stroke was five (range, 1 to 360) months. The ratio of the patients treated in the TRH in the Marmara region was 77%, but only 25% of the patients were living in the Marmara region. Duration of hospitalization was longer in the TRHs with a median of 28 days compared to those of UHs (median: 22 days) (p<0.0001). More than half of the patients (55%) were rehabilitated in the Marmara region. Time after stroke was the highest in the Southeast region with a median of 12 (range, 1 to 230) months and the lowest in the Aegean region with a median of four (range, 1 to 84) months. Conclusion: This study provides an insight into the situation of stroke rehabilitation settings and characteristics of stroke patients in Turkey. A standard method of patient evaluation and a registry system may provide data about the efficacy of stroke rehabilitation and may help to focus on the problems that hinder a better outcome.